Maxim Positive on ContraVir Pharma (CTRV) Following CMX157 Phase 2a Update

October 13, 2016 7:30 AM EDT
Get Alerts OGXI Hot Sheet
Price: $0.52 +40.54%

Rating Summary:
    3 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 27 | New: 7
Trade OGXI Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Maxim affirms ContraVir Pharmaceuticals (Nasdaq: CTRV) at Buy with a price target of $4 after the company reported positive interim data for CMX157, the Company's highly potent prodrug of tenofovir, from its ongoing Phase 2a multiple ascending dose clinical study.

Maxim noted:

  • More favorable safety profile. Patients treated with CMX157 had a much lower level of circulating tenofovir in bloodstream (tenofovir: C Max =2.8ng/mL; AUC = 34ng-h/mL) vs. patients treated with Viread (tenofovir: C Max=340 ng/mL, AUC 1910 ng-h/mL). The results demonstrated CMX157 has lower systemic tenofovir exposure, thus reducing the tenofovir-associated side effects and offering a better safety profile.
  • Next steps. ContraVir plans to continue dose escalation at the 50mg and 100mg levels following completion of the current four-week dosing regimen and independent safety review. The study is expected to complete in 4Q16, with data coming out in early 2017.
  • Conclusion. The interim data validate our belief that CMX157 potentially could be the next backbone regimen against HBV. 99% viral load reduction at only 1/12th the dose of Viread has demonstrated CMX157 as a highly potent and safe component (backbone) element in future anti-virus treatment of HBV.

For an analyst ratings summary and ratings history on OncoGenex Pharmaceuticals click here. For more ratings news on OncoGenex Pharmaceuticals click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Add Your Comment